Doxorubicin and Idarrubicin showed also significantly higher activity than the CL0292 and CL0294 compounds when assayed on pancreatic tumor cell lines harboring different KRAS mutations (KRAS G12D in SKPC, PANC1 and HPAF-II [29,30,31], and KRAS Q61H in Hs-776 [32]). The gene discussed is KRAS; the disease is pancreatic neoplasm.